GRI BIOPAR |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.43 USD | -0.05% |
|
-18.55% | -93.58% |
| Apr. 16 | GRI Bio Receives South Korea Patent for Liver Inflammatory Condition Treatments | MT |
| 2023 | Vallon Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 |
|---|---|---|
| Capitalization 1 | 40.74 | 3.695 |
| Enterprise Value (EV) 1 | 33.4 | -0.0857 |
| P/E ratio | -4.2 x | -0.42 x |
| Yield | - | - |
| Capitalization / Revenue | - | - |
| EV / Revenue | - | - |
| EV / EBITDA | -3.64 x | 0.01 x |
| EV / FCF | -6,879,622 x | 19,867 x |
| FCF Yield | -0% | 0.01% |
| Price to Book | 7 x | 1.67 x |
| Nbr of stocks (in thousands) | 227 | 425 |
| Reference price 2 | 179.4 | 8.700 |
| Announcement Date | 2/14/22 | 2/24/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Net sales | - | - | 0.1 | - | - |
| EBITDA 1 | -2.613 | -3.139 | -4.713 | -9.174 | -6.722 |
| EBIT 1 | -2.614 | -3.154 | -4.788 | -9.259 | -6.928 |
| Operating Margin | - | - | -4,788% | - | - |
| Earnings before Tax (EBT) 1 | -4.313 | -3.464 | -4.822 | -9.303 | -7.024 |
| Net income 1 | -4.313 | -3.464 | -4.822 | -9.303 | -7.024 |
| Net margin | - | - | -4,822% | - | - |
| EPS 2 | -80.78 | -29.27 | -32.10 | -42.67 | -20.77 |
| Free Cash Flow | - | -1.649 | -1.9 | -4.855 | -4.315 |
| FCF margin | - | - | -1,899.75% | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 9/11/20 | 9/11/20 | 3/29/21 | 2/14/22 | 2/24/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | 0.23 | - | - |
| Net Cash position 1 | 0.61 | 3.48 | - | 7.34 | 3.78 |
| Leverage (Debt/EBITDA) | - | - | -0.0482 x | - | - |
| Free Cash Flow | - | -1.65 | -1.9 | -4.85 | -4.32 |
| ROE (net income / shareholders' equity) | - | -206% | -548% | -426% | -172% |
| ROA (Net income/ Total Assets) | - | -80.2% | -114% | -125% | -69.4% |
| Assets 1 | - | 4.318 | 4.215 | 7.467 | 10.13 |
| Book Value Per Share 2 | 2.860 | 21.40 | -9.680 | 25.60 | 5.210 |
| Cash Flow per Share 2 | 11.50 | 25.40 | 0.7300 | 16.30 | 8.410 |
| Capex 1 | 0 | - | 0 | - | - |
| Capex / Sales | - | - | 2% | - | - |
| Announcement Date | 9/11/20 | 9/11/20 | 3/29/21 | 2/14/22 | 2/24/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- GRI Stock
- Financials GRI BIOPAR
